C4 Therapeutics Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker.